| Literature DB >> 32527607 |
Leonie J M Vergouw1, Shamiram Melhem1, Laura Donker Kaat2, Wang Z Chiu1, Demy J S Kuipers3, Guido Breedveld3, Agnita J W Boon4, Li-San Wang5, Adam C Naj6, Elizabeth Mlynarksi7, Laura Cantwell7, Marialuisa Quadri3, Owen A Ross8, Dennis W Dickson8, Gerard D Schellenberg9, John C van Swieten1, Vincenzo Bonifati3, Frank Jan de Jong10.
Abstract
The aim of this study was to explore whether variants in LRP10, recently associated with Parkinson's disease and dementia with Lewy bodies, are observed in 2 large cohorts (discovery and validation cohort) of patients with progressive supranuclear palsy (PSP). A total of 950 patients with PSP were enrolled: 246 patients with PSP (n = 85 possible (35%), n = 128 probable (52%), n = 33 definite (13%)) in the discovery cohort and 704 patients with definite PSP in the validation cohort. Sanger sequencing of all LRP10 exons and exon-intron boundaries was performed in the discovery cohort, and whole-exome sequencing was performed in the validation cohort. Two patients from the discovery cohort and 8 patients from the validation cohort carried a rare, heterozygous, and possibly pathogenic LRP10 variant (p.Gly326Asp, p.Asp389Asn, and p.Arg158His, p.Cys220Tyr, p.Thr278Ala, p.Gly306Asp, p.Glu486Asp, p.Arg554∗, p.Arg661Cys). In conclusion, possibly pathogenic LRP10 variants occur in a small fraction of patients with PSP and may be overrepresented in these patients compared with controls. This suggests that possibly pathogenic LRP10 variants may play a role in the development of PSP.Entities:
Keywords: Genetics; LRP10; Progressive supranuclear palsy; Rare variants
Mesh:
Substances:
Year: 2020 PMID: 32527607 PMCID: PMC8281359 DOI: 10.1016/j.neurobiolaging.2020.04.016
Source DB: PubMed Journal: Neurobiol Aging ISSN: 0197-4580 Impact factor: 4.673